Jack Troia
Directeur Financier/CFO chez Omnitura Therapeutics, Inc.
Profil
Jack Troia is currently the Chief Financial Officer at Omnitura Therapeutics, Inc. Prior to this, he worked as the National Director at Deloitte & Touche.
Postes actifs de Jack Troia
| Sociétés | Poste | Début |
|---|---|---|
Omnitura Therapeutics, Inc.
 Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | Directeur Financier/CFO | - |
Anciens postes connus de Jack Troia
| Sociétés | Poste | Fin |
|---|---|---|
Deloitte & Touche
 Deloitte & Touche Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche provides audit, enterprise risk management, and financial advisory services. The company delivers services in four professional areas: audit, tax, consulting, and financial advisory services. It provides its clients with global services such as entering foreign markets, raising funds, and investing in Mainland China. The company was founded in June, 2003 and is headquartered in Taipei, Taiwan. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | Health Technology |
Deloitte & Touche
Deloitte & Touche Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche provides audit, enterprise risk management, and financial advisory services. The company delivers services in four professional areas: audit, tax, consulting, and financial advisory services. It provides its clients with global services such as entering foreign markets, raising funds, and investing in Mainland China. The company was founded in June, 2003 and is headquartered in Taipei, Taiwan. | Commercial Services |
